# The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein

Study · id `cardio:ct-nct02562183` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02562183](<https://clinicaltrials.gov/study/NCT02562183>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02562183

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2186 participants.

## Technical summary

Registry record NCT02562183. Allocation not applicable; no masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2018-11-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2186 participants (planned count; ClinicalTrials.gov record NCT02562183, source copy `cardio:ctgov-nct02562183-2018-01-17`, retrieved 2026-10-26)
- Start date: 2015-08 (registry gives no type) (ClinicalTrials.gov record NCT02562183, source copy `cardio:ctgov-nct02562183-2018-01-17`, retrieved 2026-10-26)
- Primary completion: 2018-11-30 (anticipated) (ClinicalTrials.gov record NCT02562183, source copy `cardio:ctgov-nct02562183-2018-01-17`, retrieved 2026-10-26)
- Completion: 2018-11-30 (anticipated) (ClinicalTrials.gov record NCT02562183, source copy `cardio:ctgov-nct02562183-2018-01-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02562183, source copy `cardio:ctgov-nct02562183-2018-01-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02562183-2018-01-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
- Condition: Cerebral Infarction
- Intervention (Drug): kallikrein
- Lead sponsor: Techpool Bio-Pharma Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: b18b530e4df452b6f0802be7f5427af0fe50e3babe2030f4f582f175e6eff3cf
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
